Loading...
XSTO
ORX
Market cap71mUSD
Jun 16, Last price  
20.00SEK
1D
2.56%
1Q
34.77%
Jan 2017
-46.81%
IPO
-77.77%
Name

Orexo AB

Chart & Performance

D1W1MN
P/E
—
P/S
1.17
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.50%
Rev. gr., 5y
-6.93%
Revenues
590m
-7.64%
62,352,000131,956,0000233,346,000236,104,000210,499,000199,614,000326,278,000429,355,000570,316,000643,338,000705,800,000643,700,000783,100,000844,800,000663,600,000565,000,000624,300,000638,800,000590,000,000
Net income
-203m
L+58.22%
-43,249,000-32,943,0000-103,054,000-98,079,000-89,246,000-392,009,000-85,863,000-154,936,000-56,584,000-197,987,00029,000,00023,200,000137,900,000219,100,000-84,400,000-223,500,000-177,600,000-128,300,000-203,000,000
CFO
-33m
L-65.68%
-45,382,000-25,279,000-160,485,000-101,490,000-133,927,000-42,967,000-117,228,00028,668,000-263,201,000-487,300,000-102,193,000156,200,000146,600,000242,000,000287,000,00016,800,000-229,000,000-156,600,000-95,000,000-32,600,000
Earnings
Jul 15, 2025

Profile

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
URL
https://orexo.se/
IPO date
Nov 09, 2005
Employees
120
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
590,000
-7.64%
638,800
2.32%
624,300
10.50%
Cost of revenue
768,700
761,500
821,900
Unusual Expense (Income)
NOPBT
(178,700)
(122,700)
(197,600)
NOPBT Margin
Operating Taxes
12,400
(12,000)
7,200
Tax Rate
NOPAT
(191,100)
(110,700)
(204,800)
Net income
(203,000)
58.22%
(128,300)
-27.76%
(177,600)
-20.54%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
10,000
20,900
20,600
Long-term debt
482,000
478,300
563,800
Deferred revenue
Other long-term liabilities
24,000
11,600
10,200
Net debt
368,700
328,200
451,300
Cash flow
Cash from operating activities
(32,600)
(95,000)
(156,600)
CAPEX
(4,600)
(18,500)
(23,900)
Cash from investing activities
(5,300)
200,800
(234,700)
Cash from financing activities
(15,500)
(70,100)
(21,400)
FCF
(218,800)
(125,600)
(218,700)
Balance
Cash
123,300
171,000
351,800
Long term investments
(218,700)
Excess cash
93,800
139,060
101,885
Stockholders' equity
(1,757,000)
(1,622,000)
Invested Capital
373,700
2,301,300
2,361,400
ROIC
ROCE
EV
Common stock shares outstanding
34,465
34,413
34,352
Price
17.50
13.20%
15.46
-18.03%
18.86
-45.33%
Market cap
603,141
13.37%
532,031
-17.88%
647,874
-45.28%
EV
971,841
860,231
1,099,174
EBITDA
10,500
(45,600)
(128,900)
EV/EBITDA
92.56
Interest
41,200
27,800
Interest/NOPBT